Protein (5)
Launched (5)
Human (5)
His Tag & Avi Tag (2)His Tag (3)
Biotin-labeled (1)Unconjugated (2)AF488 Labeled (1)PE Labeled (1)
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| VVN-001 | VVN001; VVN-001 | Phase 3 Clinical | VivaVision Biotech Inc | Dry Eye Syndromes; Xerophthalmia | Details |
| P-28-R | P-28- R | Phase 1 Clinical | Canimguide Therapeutics | Head and Neck Neoplasms | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Odulimomab | Approved | Immunotech SAS | Antilfa | France | Graft vs Host Disease; Rejection of renal transplantation | null | 1997-01-01 | Rejection of renal transplantation; Graft vs Host Disease | Details |

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



